نتایج جستجو برای: lenalidomide

تعداد نتایج: 3060  

Journal: :Blood 2021

Abstract Carfilzomib is an epoxyketone proteasome inhibitor of second generation, proved to be effective and safe in relapsed refractory Multiple Myeloma (rrMM), combination with dexamethasone or lenalidomide dexamethasone. In this retrospective observational trial, it has been evaluated efficacy safety carfilzomib, lenalidomide-dexamethasone (KRD) as salvage regimen patients rrMM, lenalidomide...

2017
X Leleu C Kyriakou I Vande Broek P Murphy P Bacon P Lewis H Gilet B Arnould M T Petrucci

Treatment advances for multiple myeloma (MM) that have prolonged survival emphasise the importance of measuring patients' health-related quality of life (HRQoL) in clinical studies. HRQoL/functioning and symptoms of patients with relapsed/refractory MM (RRMM) receiving second- or third-line lenalidomide or bortezomib treatment were measured in a prospective European multicentre, observational s...

Journal: :Haematologica 2015
Naval Daver Jorge Cortes Kate Newberry Elias Jabbour Lingsha Zhou Xuemei Wang Sherry Pierce Tapan Kadia Koji Sasaki Gautam Borthakur Farhad Ravandi Naveen Pemmaraju Hagop Kantarjian Srdan Verstovsek

Ruxolitinib and lenalidomide may target distinct clinical and pathological manifestations of myelofibrosis and prevent therapy-related worsening of blood cell counts. To determine the efficacy and safety of the combination in patients with myelofibrosis, patients were given 15 mg ruxolitinib orally twice daily in continuous 28-day cycles, plus 5 mg lenalidomide orally once daily on days 1-21. T...

2017
Andrew Toma Aaron P Rapoport Allen Burke Ashutosh Sachdeva

Multiple myeloma is a plasma cell dyscrasia accounting for 10% of haematologic malignancies. Lenalidomide is an immunomodulatory drug analogous to thalidomide that is approved for use in patients with myelodysplastic syndrome, and in combination with dexamethasone for refractory or relapsed multiple myeloma. Lenalidomide is preferred to thalidomide because of reduced toxicity, and pulmonary sid...

Journal: :Blood 2012
Rami S Komrokji Jeffrey E Lancet Arlene S Swern Nianhang Chen Jennifer Paleveda Richard Lush Hussain I Saba Alan F List

The erythropoietic effects of lenalidomide are cytokine dependent, suggesting that the erythroid hematologic improvement (HI-E) rate may be augmented by combined treatment (CT) with recombinant human erythropoietin (rhu-EPO) in myelodysplastic syndrome (MDS). In the present study, we explored the benefits of CT and the relationship between lenalidomide pharmacokinetics and hematologic toxicity ...

2017
Manh-Cuong Vo Thanh-Nhan Nguyen-Pham Hyun-Ju Lee Thangaraj Jaya Lakshmi Seoyun Yang Sung-Hoon Jung Hyeoung-Joon Kim Je-Jung Lee

In this study, we investigated efficacy of lenalidomide in combination with tumor antigen-loaded dendritic cells (DCs) in murine colon cancer model. MC-38 cell lines were injected subcutaneously to establish colon cancer-bearing mice. After tumor growth, lenalidomide (50 mg/kg/day) was injected intraperitoneally on 3 consecutive days in combination with tumor antigen-loaded DC vaccination on da...

Journal: :Clinical cancer research : an official journal of the American Association for Cancer Research 2007
Howard A Fine Lyndon Kim Paul S Albert J Paul Duic Hilary Ma Wei Zhang Tanyifor Tohnya William D Figg Cheryl Royce

PURPOSE Inhibition of angiogenesis represents a promising new therapeutic strategy for treating primary malignant brain tumors. Lenalidomide, a potent analogue of the antiangiogenic agent thalidomide, has shown significant activity in several hematologic malignancies, and therefore we chose to explore its tolerability and activity in patients with primary central nervous system tumors. EXPERI...

2017
M A Dimopoulos A K Stewart T Masszi I Špička A Oriol R Hájek L Rosiñol D Siegel G G Mihaylov V Goranova-Marinova P Rajnics A Suvorov R Niesvizky A Jakubowiak J San-Miguel H Ludwig S Ro S Aggarwal P Moreau A Palumbo

Carfilzomib, a proteasome inhibitor, is approved as monotherapy and in combination with dexamethasone or lenalidomide-dexamethasone (Rd) for relapsed or refractory multiple myeloma. The approval of carfilzomib-lenalidomide-dexamethasone (KRd) was based on results from the randomized, phase 3 study ASPIRE (NCT01080391), which showed KRd significantly improved progression-free survival (PFS) vs R...

Journal: :Blood 2016
Valeria Magarotto Sara Bringhen Massimo Offidani Giulia Benevolo Francesca Patriarca Roberto Mina Antonietta Pia Falcone Lorenzo De Paoli Giuseppe Pietrantuono Silvia Gentili Caterina Musolino Nicola Giuliani Annalisa Bernardini Concetta Conticello Stefano Pulini Giovannino Ciccone Vladimír Maisnar Marina Ruggeri Renato Zambello Tommasina Guglielmelli Antonio Ledda Anna Marina Liberati Vittorio Montefusco Roman Hajek Mario Boccadoro Antonio Palumbo

Lenalidomide-dexamethasone improved outcome in newly diagnosed elderly multiple myeloma patients. We randomly assigned 662 patients who were age ≥65 years or transplantation-ineligible to receive induction with melphalan-prednisone-lenalidomide (MPR) or cyclophosphamide-prednisone-lenalidomide (CPR) or lenalidomide plus low-dose dexamethasone (Rd). The primary end point was progression-free sur...

Journal: :International journal of radiation oncology, biology, physics 2009
Jan Drappatz Eric T Wong David Schiff Santosh Kesari Tracy T Batchelor Lisa Doherty Debra Conrad Lafrankie Naren Ramakrishna Stephanie Weiss Sharon T Smith Abigail Ciampa Jennifer Zimmerman Louis Ostrowsky Karly David Andrew Norden Loretta Barron Christine Sceppa Peter M Black Patrick Y Wen

PURPOSE To define the maximum tolerated dose (MTD) of lenalidomide, an analogue of thalidomide with enhanced immunomodulatory and antiangiogenic properties and a more favorable toxicity profile, in patients with newly diagnosed glioblastoma multiforme (GBM) when given concurrently with radiotherapy. PATIENTS AND METHODS Patients with newly diagnosed GBM received radiotherapy concurrently with...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید